http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0429189-A3

Outgoing Links

Predicate Object
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-20
filingDate 1990-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 1992-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-0429189-A3
titleOfInvention A method of treating anxiety related disorders using sertraline
abstract The use of the compound (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine or a pharmaceutically acceptable salt thereof for the manufacture of a medicament to treat or prevent social phobia and the symptoms associated with such a disorder.
priorityDate 1989-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0357369-B1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129182589
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129471329
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID53893383
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8640
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128104979
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID68617
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226415961
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5203
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129471331

Total number of triples: 24.